Lack of Predictive Factors in Late Recurrence of Stage I Melanoma

Tahery, Dan P.; Moy, Ronald L.

doi:10.1111/j.1365-4362.1992.tb03980.x

Cited by 20 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 Alternatively, if dormancy is a period of tumor stasis, with complete inhibition of net growth, and clinical recurrence results from an event that allows unrestrained proliferation, outcomes after recurrence of late and early patients should be equally poor. 14,13, 25, 29 Our data suggest each scenario is partially correct.…”

Section: Discussionmentioning

confidence: 70%

“…Most previous series of late recurrence lacked comparator populations and were unable to formally analyze risk factors. 1,12,14,17,18,21,23–26 Several suggested it was more common among pre-menopausal women, possibly with lower extremity primary lesions, while others disputed the suggestion. Other series used the overall melanoma population or those with no recurrence as comparators.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy

Faries¹,

Steen²,

Ye³

et al. 2013

Journal of the American College of Surgeons

View full text Add to dashboard Cite

Background For patients with melanoma, if there has been no recurrence of disease 10 years after initial treatment, additional disease is felt to be very unlikely. However, such late recurrence are known to occur. The frequency of this phenomenon and its clinical significance are not well characterized due to the difficulty in obtaining relevant data. We examined a large, mature, institutional database to evaluate late recurrence. Study Design The late recurrence cohort was defined as having a DFI of ≥10 years after potentially curative treatment and was compared to an early recurrence cohort recurring within 3 years. Actuarial late recurrence frequency and factors associated with late recurrence were examined. Post-recurrence overall and melanoma-specific survival and prognostic variables were analyzed. Results Among all patients, 408 exhibited late recurrence (mean DFI 15.7 years). For patients who received primary treatment at our institution with ≥10 years follow-up, 327/4731 (6.9%) showed late recurrence. On an actuarial basis, late recurrence rates were 6.8% and 11.3% at 15 and 20 years respectively for those with no recurrence at 10 years. Late recurrence was associated with both tumor (thin, non-ulcerated, non-head/neck, node negative) and patient (younger age, less male predominant) characteristics. Multivariate analysis confirmed younger age, thinner and node negative tumors in the late recurrence group. Late recurrences were more likely to be distant, but were associated with better post-recurrence survival on univariate and multivariate analyses. Conclusions Late melanoma recurrence is not rare. It occurs more frequently in certain clinical groups and is associated with improved post-recurrence survival.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy

Faries¹,

Steen²,

Ye³

et al. 2013

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

“…Review of the literature on late local recurrences revealed only 18 cases that fit the criteria set above (Table 1) [1,[4][5][6][7][8][9][10][11]. However, unlike the current case, none of these patients experienced local recurrences in the same site more than once.…”

Section: Discussionmentioning

confidence: 91%

“…The Breslow thickness averaged 1.18 mm (range 0.4-1.85 mm). At follow up of varying lengths (range 5-216 months excluding the Otsu paper), five patients died of disease, four were alive with no evidence of disease, four were only reported as alive with no comment regarding disease status, three statuses were unknown, one experienced two local recurrences, and one had a regional and systemic disease in four years time but was still being treated at the time of reporting [3][4][5][6][7][8][9][10][11]. melanoma in the dermis with negative surgical margins.…”

Section: Review Of the Literaturementioning

confidence: 99%

The history of dermatology, venereology and dermatopathology in different countries - Argentina

Beguerie¹

2016

Glob Dermatol

View full text Add to dashboard Cite

“…Die Wahrscheinlichkeit einer spä-ten Progression nach 10 und mehr Jahren erscheinungsfreiem Intervall wird je nach Größe und Zusammensetzung des untersuchten Kollektivs und der Dauer der Nachbeobachtung mit 0,84-7% angegeben [4,7,15,19,24,36,42]. Aus der Reihe fällt der sehr hohe Anteil von 25% bei Crowley et al (1990).…”

Section: Malignant Melanoma · Late Metastasesunclassified

Melanomerstmetastasen nach 10 und mehr Jahren Erscheinungsfreiheit

1997

View full text Add to dashboard Cite

36 (3.5%) of 1015 patients who had ten or more years of follow-up after treatment of invasive malignant melanomas (stage I and II, UICC 1978) in Hornheide 1967-1984 developed late metastases. The mean disease-free interval was 12.5 years. These patients were younger (mean age of 45.8 years) compared to the age of all melanoma patients at the time of primary therapy. The rate of late relapses was 2.8% in women (20/705) and 5% in men (16/310). In melanomas located on the trunk or on the legs in male individuals, the relapse was twice as high as in females. The median tumor thickness in patients with late progression was 1.5 mm; in patients without relapse 1.2 mm. The well known association of tumor thickness with the risk of metastases disappeared after a 10 years disease-free interval. The frequency of metastases (3.5%) did not vary in different thickness classes from 0.76 mm to 3 mm or more. Melanomas with a Breslow thickness < 0.75 mm had a risk of only 1.4%. 23 patients (64%) developed distant, only 13 (36%) regional late metastases as first evidence of recurrent disease. The survival of these patients correlated neither to the duration of previous relapse-free follow up, nor to site of the primary lesion nor to sex. It correlated only to the site of metastases: 83% of all patients with distant late metastases had a remaining life time of 14 months or less, but patients with regional metastases survived more than 7 years in 69% of the cases. We have been unable to define risk factors for late metastases.

show abstract

Lack of Predictive Factors in Late Recurrence of Stage I Melanoma

Cited by 20 publications

References 12 publications

Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy

Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy

The history of dermatology, venereology and dermatopathology in different countries - Argentina

Melanomerstmetastasen nach 10 und mehr Jahren Erscheinungsfreiheit

Contact Info

Product

Resources

About